
Alumis Inc (ALMS) Stock Forecast & Price Target
Alumis Inc (ALMS) Analyst Ratings
Bulls say
Alumis is currently a financially risky investment as there is potential for the market for envu to be smaller than expected due to competition from other therapies and challenges in penetrating the market. Additionally, Alumis may face financing risks as it continues to expand R&D and commercialization efforts before becoming profitable. However, with a reported net loss of $93.1MM and a strong balance sheet with $569.5MM in cash, Alumis is positioned to potentially overcome these challenges and achieve a valuation of $3.8B, driven by envu's potential in PsO and SLE. Risks to keep in mind include delays in regulatory approvals, competition in the I&I space, and potential equity dilution.
Bears say
Alumis is currently in the clinical stage of development, and despite their promising phase II and phase III data for their candidates in some indications, there is still the possibility for pivotal trials in others to not meet efficacy endpoints due to variability in patients or disease trajectories. Additionally, with a crowded market and established competitors in the biopharmaceutical industry, Alumis's current pipeline may struggle to achieve a competitive benefit/risk profile in the long-term. Given these concerns, the financial analyst maintains a Neutral rating on the stock and has set a 12-month price target of $25.
This aggregate rating is based on analysts' research of Alumis Inc and is not a guaranteed prediction by Public.com or investment advice.
Alumis Inc (ALMS) Analyst Forecast & Price Prediction
Start investing in Alumis Inc (ALMS)
Order type
Buy in
Order amount
Est. shares
0 shares